Dyadic Added to Biofuel Digest Index of Bioeconomy Stocks

JUPITER, Fla., June 16, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today that Biofuels Digest has selected Dyadic to be included in its Biofuel Digest Index as part of the annual rebalancing of publicly traded stocks included in the index.

Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Danai Brooks, Chief Operating Officer of Dyadic, noted, "Dyadic has gained significant momentum as a critical technology component in the biofuel and bio-based chemical economy.  Earlier this year, Biofuel Digest named Dyadic in the 50 Hottest Companies in Bioenergy.  Abengoa Bioenergy, a Dyadic technology licensee, is opening a first-of-its-kind cellulosic 25 million gallon biofuel plant in Hugoton, Kansas in early July.  We believe that our class-leading enzyme technology and on-site licensing model are the right mix to be successful in this industry." 

Biofuel Digest is the world's most widely read biofuel daily covering bioenergy production, finance, policy and research. The Biofuel Digest Index has tracked the bioeconomy since August 2007. Stocks are weighted to reflect market cap, and the extent to which diversified industrial companies are focused on a bio-based strategy.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.

SOURCE Dyadic International, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED